BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-650-8895020
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
OptionableNot Optionable
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) issued its earnings results on Thursday, December, 6th. The biotechnology company reported ($0.02) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.02). The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.02 million. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
1 brokers have issued 12-month price targets for Biopharmx's stock. Their forecasts range from $1.50 to $1.50. On average, they expect Biopharmx's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 1,334.0% from the stock's current price. View Analyst Price Targets for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.
Has Biopharmx been receiving favorable news coverage?
News headlines about BPMX stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biopharmx earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Biopharmx?
Biopharmx saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,928,170 shares, an increase of 11.4% from the January 15th total of 1,731,107 shares. Based on an average daily trading volume, of 2,428,126 shares, the short-interest ratio is currently 0.8 days. Approximately 1.0% of the shares of the company are sold short. View Biopharmx's Current Options Chain.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include IntelGenx Technologies (IGX), CEL-SCI (CVM), Orgenesis (ORGS), Botanix Pharmaceuticals (BOT), Promis Neurosciences (PMN), Protalix Biotherapeutics (PLX), Pediapharm (PDP), Ampio Pharmaceuticals (AMPE), Helix Biopharma (HBP), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Imugene (IMU), Antibe Therapeutics (ATE), Asterias Biotherapeutics (AST) and Noxopharm (NOX).
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
- Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
- Dr. José Zayas, Sr. VP of Operations
- Ms. Joyce Goto, VP ,CAO & Controller (Age 46)
- Dr. R. Kehl Sink, Sr. VP of Intellectual Property & Legal
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.1046.
How big of a company is Biopharmx?
Biopharmx has a market capitalization of $22.84 million. Biopharmx employs 27 workers across the globe.
What is Biopharmx's official website?
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
